Dr. Argiles on Study of Carcinoembryonic Antigen T-Cell Bispecific Antibody

Guillem Argiles, MD
Published: Wednesday, Jul 05, 2017



Guillem Argiles, MD, staff member, Gastrointestinal Malignancies Division, Vall d’Hebron University Hospital, discusses a carcinoembryonic antigen T-cell bispecific antibody.

In a study of patients with metastatic colorectal cancer, the novel carcinoembryonic antigen T-cell bispecific (CEA-TCB) antibody was evaluated as a monotherapy and in combination with atezolizumab (Tecentriq).

Results showed evidence of antitumor activity during dose escalation with CEA-TCB monotherapy, and a manageable safety profile was observed with the atezolizumab combination as well.
 


Guillem Argiles, MD, staff member, Gastrointestinal Malignancies Division, Vall d’Hebron University Hospital, discusses a carcinoembryonic antigen T-cell bispecific antibody.

In a study of patients with metastatic colorectal cancer, the novel carcinoembryonic antigen T-cell bispecific (CEA-TCB) antibody was evaluated as a monotherapy and in combination with atezolizumab (Tecentriq).

Results showed evidence of antitumor activity during dose escalation with CEA-TCB monotherapy, and a manageable safety profile was observed with the atezolizumab combination as well.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x